Six-month treatment with risperidone showed no benefit over placebo in treating patients with military-related PTSD who were resistant to treatment with selective serotonin-reuptake inhibitor (SSRI) antidepressants, according to a report in August issue of
the Journal of the American Medical Association. The study was a six-month, randomized, double-blind, placebo-controlled trial conducted from February 2007 to February 2010 at 23 Veterans Administration outpatient medical centers. Despite limited evidence supporting the practice, second-generation antipsychotics—of which risperidone is one—are commonly used for SSRI-resistant symptoms of PTSD, the authors say.
(Image: Shutterstock)
